[Kim Sungjin, Edaily Reporter] Huons Group is strengthening its presence in the rapidly growing Middle Eastern aesthetic medicine market through its participation in a premier dermatology and aesthetic exhibition in Dubai, UAE.

Humedix, Huons Meditech, and Huons BioPharma under Huons Group announced on the 11th their participation in the ‘Dubai Derma 2026’, held from September 8 to 10 at the Dubai World Trade Centre, to showcase their core aesthetic portfolios and network with global industry leaders.

Recognized as a major international platform for dermatology, aesthetics and laser medicine across the Middle East, North Africa and the Indian Subcontinent, Dubai Derma 2026 brings together leading physicians, healthcare professionals, industry leaders and global aesthetic brands.

The group’s participation reflects its broader strategy of accelerating overseas growth by expanding its aesthetic portfolio and introducing differentiated pharmaceutical and medical solutions to new markets. Huons Group is seeking to build a stronger regional presence through both product expansion and clinical engagement with local medical professionals.

Humedix pushed for market expansion in the Middle East by exhibiting its flagship aesthetic filler brand, ‘elravie’. A key highlight of Humedix’s participation was a dedicated clinical seminar, titled “The Visible Signature: K-Beauty Principles for Lips, Jawline and Hands,” presented by Dr. Chris GunWoo Kim, Chief Director of Cellinique Clinic, on September 8, the first day of the event. Drawing on clinical experience, Dr. Kim addressed three increasingly important areas in modern aesthetic medicine: the lips, jawline and hands.

Huons Meditech captured the attention of buyers by showcasing its global steady-seller, ‘Dermashine Pro’, alongside its next-generation product, ‘Dermashine DUO RF’. The ‘Dermashine DUO RF’ is a hybrid medical device that simultaneously delivers radiofrequency (RF) stimulation and drug injection, significantly reducing both procedure time and patient discomfort. It features differentiated technology that shortens injection time and alleviates pain through advanced injection mechanisms.

Huons BioPharma promoted its botulinum toxin product, Hutox, along with its proprietary technology. As of January this year, Hutox has secured product approvals in 17 overseas markets, including China, Russia, Southeast Asia (such as Thailand), and the Middle East (such as Iraq), and is currently undergoing the product approval process in Brazil.

For Huons Group, Dubai Derma represents more than an opportunity to display products. The group is using the event as a platform to establish direct relationships with regional medical professionals, understand evolving treatment preferences in the Middle East and identify opportunities for long-term commercial and clinical partnerships.

An official from Huons Group stated, "The Middle East is becoming an increasingly important market for aesthetic medicine, and Dubai Derma provides an important platform for us to engage directly with physicians and industry partners in the region." The official added, "Going forward, Huons Group will continue to identify innovative treatment solutions and strengthen long-term partnerships across the Middle Eastern market."

Huons Group’s participation in ‘Dubai Derma 2026’ marks another step in the group’s continued international expansion, with the Middle East emerging as an important strategic market for its growing aesthetic business.